Epizyme Inc (NASDAQ:EPZM)’s share price traded down 5.3% on Monday . The company traded as low as $7.44 and last traded at $7.50. 637,680 shares were traded during mid-day trading, an increase of 29% from the average session volume of 493,277 shares. The stock had previously closed at $7.92.
A number of equities analysts recently weighed in on the stock. Morgan Stanley reduced their target price on shares of Epizyme from $12.00 to $11.00 and set a “hold” rating for the company in a research note on Monday, November 5th. Zacks Investment Research lowered shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Oppenheimer set a $27.00 target price on shares of Epizyme and gave the stock a “buy” rating in a research note on Thursday, November 15th. BidaskClub raised shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. Finally, Leerink Swann assumed coverage on shares of Epizyme in a research note on Monday, September 24th. They issued a “market perform” rating and a $11.00 target price for the company. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Epizyme presently has a consensus rating of “Hold” and an average target price of $20.50.
The company has a market capitalization of $627.01 million, a price-to-earnings ratio of -3.44 and a beta of 1.89.
In other Epizyme news, Director David M. Mott acquired 416,667 shares of Epizyme stock in a transaction dated Friday, October 5th. The stock was bought at an average cost of $9.00 per share, for a total transaction of $3,750,003.00. Following the purchase, the director now directly owns 12,088 shares in the company, valued at approximately $108,792. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 21.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of EPZM. Voya Investment Management LLC boosted its stake in shares of Epizyme by 95.0% during the 2nd quarter. Voya Investment Management LLC now owns 1,182,983 shares of the biopharmaceutical company’s stock worth $16,029,000 after buying an additional 576,436 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Epizyme by 259.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 669,300 shares of the biopharmaceutical company’s stock worth $7,095,000 after buying an additional 483,300 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Epizyme by 10.4% during the 2nd quarter. BlackRock Inc. now owns 4,303,720 shares of the biopharmaceutical company’s stock worth $58,315,000 after buying an additional 406,541 shares during the last quarter. Sofinnova Ventures Inc acquired a new position in shares of Epizyme during the 3rd quarter worth about $3,087,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Epizyme during the 3rd quarter worth about $2,535,000. Institutional investors own 71.03% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/2018/11/20/epizyme-epzm-trading-down-5-3/3014626.html.
About Epizyme (NASDAQ:EPZM)
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.